Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2017-02-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
独立董事关于子公司出售股权的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent opinion from the independent directors regarding the sale of a subsidiary's equity. It discusses the fairness and rationale of the transaction but does not contain financial statements or detailed financial data. It is not a full report but an opinion related to a specific transaction. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement related to corporate governance and transaction approval, but not a full M&A filing or financial report.
2017-02-08 Chinese
第九届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution regarding the sale of a subsidiary's equity. It details the board's approval of the transaction, the rationale behind it, and confirms that it does not require shareholder approval or regulatory consent. There is no financial report or detailed financial data presented, nor is it a full annual or interim report. It is not a call transcript, earnings release, or capital update. The document is a formal announcement of a board decision, which fits the category of Board/Management Information (MANG). The document length is short and focused on management decisions rather than financial results or regulatory filings.
2017-02-08 Chinese
关于子公司出售股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company 马应龙药业集团股份有限公司 regarding the sale of a 51% equity stake in its subsidiary 湖北天下明药业有限公司 by its wholly-owned subsidiary 武汉马应龙大药房连锁股份有限公司 to an individual named 朱清平. The document details the transaction overview, parties involved, transaction terms, pricing basis, contractual obligations, and the impact on the company. It is a formal disclosure of a capital transaction involving a subsidiary's equity sale. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a proxy statement, voting result, or management change announcement. It is a specific update on a financing/capital transaction (equity sale). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5576 characters) and detailed transaction terms support this classification with high confidence.
2017-02-08 Chinese
关于获得《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a pharmaceutical GMP (Good Manufacturing Practice) certificate from a regulatory authority. It details the certificate information, production workshop details, product market situation, and the impact on the company. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no legal proceedings, no capital changes, and no earnings information. The document is a regulatory announcement about certification compliance and operational capability, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-02-08 Chinese
关于股东股权解除质押暨继续质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the release and re-pledging of shares by a major shareholder. It details the number of shares involved, the pledge and release dates, and the shareholder's stake percentage. There is no financial report, earnings data, or management discussion. The content focuses on share pledge status, which relates to capital structure and financing activities. The document length is short (665 characters), and it is an announcement rather than a detailed report. Therefore, it fits best under Capital/Financing Update (CAP).
2016-12-29 Chinese
关于股东股权解除质押暨继续质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the release and re-pledging of shareholder equity shares by a controlling shareholder. It details the number of shares involved, the pledge terms, and the shareholder's financial status. There is no financial report, earnings data, or management discussion. The content fits the category of a Major Shareholding Notification, as it involves changes in significant share ownership levels and pledging status. The document is short and focused on share pledge information, not a full report or regulatory filing. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2016-11-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.